Human immunodeficiency virus type 1 polymerase peptide–Major histocompatibility complex class I complex (HIV Pol–MHC I)

The Human immunodeficiency virus type 1 (HIV-1) polymerase (Pol) peptide–Major Histocompatibility Complex (MHC) class I complex is a cell-surface molecular assembly consisting of a peptide fragment derived from the HIV-1 Pol polyprotein bound within the groove of an MHC class I molecule (UniProt P03366). The Pol protein, which encompasses essential viral enzymes like reverse transcriptase and integrase, is highly conserved across different HIV strains, making its derived epitopes reliable targets for immune recognition (PubMed: 28416518). These complexes function as the primary signal for CD8+ cytotoxic T lymphocytes (CTLs), which utilize their T-cell receptors (TCRs) to identify and eliminate infected cells presenting these viral antigens (PubMed: 31064777). In modern drug development, these complexes are targeted by advanced immunotherapies, including TCR-engineered T cells and bispecific molecules such as Immune mobilizing monoclonal TCRs Against Virus (ImmTAVs), which aim to enhance the clearance of the latent HIV reservoir (Immunocore, 2023). Therapeutic success depends on the stability of the peptide-MHC interaction and the specificity of the targeting agent to avoid cross-reactivity with human self-peptides, which could lead to off-target toxicity (PubMed: 32518144). Additionally, the potential for viral escape through mutations in the Pol epitope remains a significant challenge for long-term efficacy (PubMed: 25143361).

Other names

HIV-1 Pol–HLA complexHIV Pol–MHC-IHIV-1 Pol peptide–MHC class IHIV Pol–HLA-A*02:01 complex

Recognition by T-cell receptors (TCRs) to trigger cytotoxic T lymphocyte (CTL) mediated lysis of infected cells.